Repare Therapeutics (RPTX) Price & Analysis

Compare

439 Followers

RPTX Stock Chart & Stats

$1.72

-$0.07(-5.15%)

At close: Jan 08 4:00 PM EST

$1.72

-$0.07(-5.15%)

Day’s Range― - ―

52-Week Range$0.89 - $4.07

Previous CloseN/A

Volume283.97K

Average Volume (3M)138.92K

Market Cap

$76.47M

Enterprise Value-$49.16M

Total Cash (Recent Filing)$109.47M

Total Debt (Recent Filing)$649.00K

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Mar 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding42,959,170

10 Day Avg. Volume221,679

30 Day Avg. Volume138,921

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)0.37

Price to Sales (P/S)1.04

P/FCF Ratio-0.73

Enterprise Value/Market Cap-0.64

Enterprise Value/Revenue-0.92

Enterprise Value/Gross Profit-1.27

Enterprise Value/Ebitda0.45

Forecast

1Y Price Target

$3.00

Price Target Upside74.42% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentEarly signs of efficacy and favorable safety profiles will facilitate further development of RP-1664 and RP-3467.

Financial StabilityThe company has a cash runway guidance through 2027, supported by $109.5 million in cash, equivalents, and marketable securities as of June 30th.

Strategic PartnershipsRepare Therapeutics Inc. continues to seek strategic alternatives and partnerships across its portfolio, including outlicensing agreements that have generated upfront payments and equity stakes.

Bears Say

Clinical Trial OutcomesThe upcoming clinical trial results are based on a small and heterogeneous patient set, making it unlikely to lead to a 'proof-of-concept type of conclusion.'

Drug ViabilityInitial RP-1664 data raises questions over its viability—lowering PT to $3.

Operational ChallengesA previous 75% workforce reduction was approved by the board, indicating potential operational or financial challenges.

Repare Therapeutics News

Repare Therapeutics price target lowered to $3 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Repare Therapeutics (RPTX) to $3 from $5 and keeps a...

18d ago

RPTX

Repare Therapeutics’ Promising Study on Advanced Solid Tumors: A Closer Look

Repare Therapeutics Inc (($RPTX)) announced an update on their ongoing clinical study. Repare Therapeutics Inc. is conducting a...

18d ago

RPTX

Repare Therapeutics Unveils Phase 1 LIONS Trial Data

An update from Repare Therapeutics ( ($RPTX) ) is now available. On October 22, 2025, Repare Therapeutics announced...

23d ago

RPTX

Repare Therapeutics: Strategic Partnerships and Cautious Optimism Amid Uncertain Trial Outcomes Justify Hold Rating

LifeSci Capital analyst Charles Zhu has maintained their neutral stance on RPTX stock, giving a Hold rating on...

3M ago

RPTX

Repare Therapeutics Reports Q2 2025 Results and Strategic Moves

Repare Therapeutics Inc ( ($RPTX) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

RPTX

Repare Therapeutics Announces Licensing Deal and Strategic Updates

An update from Repare Therapeutics ( ($RPTX) ) is now available. Repare Therapeutics has entered a worldwide licensing...

3M ago

RPTX

Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year

Reports Q2 revenue $250,000, consensus $1.67M. “We remain focused on exploring strategic alternatives and partnerships across our portfolio...

3M ago

RPTX

Repare Therapeutics Signs Licensing Deal with Debiopharm

An announcement from Repare Therapeutics ( ($RPTX) ) is now available. On July 15, 2025, Repare Therapeutics entered...

4M ago

RPTX

Closing Bell Movers: Victory Capital gains on S&P 400 inclusion

In the opening 90 minutes of the evening session, U.S. equity futures are down slightly with a 0.2%...

4M ago

BHF

BLK

Repare Therapeutics enters licensing pact with Debiopharm for Lunresertib

Repare Therapeutics (RPTX) announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A., a...

4M ago

RPTX

Repare Therapeutics Updates Severance Benefits for Executives

Repare Therapeutics ( ($RPTX) ) has issued an announcement. On June 13, 2025, Repare Therapeutics Inc.’s Compensation Committee...

5M ago

RPTX

Repare Therapeutics Holds Annual Shareholder Meeting

Repare Therapeutics ( ($RPTX) ) has shared an announcement. On June 17, 2025, Repare Therapeutics held its Annual...

5M ago

RPTX

Repare Therapeutics Strengthens Leadership with New Executive Appointment

Repare Therapeutics ( ($RPTX) ) just unveiled an update. Repare Therapeutics Inc. has announced an amendment to its...

5M ago

RPTX

Repare Therapeutics Advances Strategic Partnerships and Clinical Trials Amid Financial Updates

Repare Therapeutics ( ($RPTX) ) has shared an announcement. Repare Therapeutics has announced a strategic partnership with DCx...

6M ago

RPTX

RPTX FAQ

What was Repare Therapeutics Inc’s price range in the past 12 months?

Repare Therapeutics Inc lowest stock price was $0.89 and its highest was $4.07 in the past 12 months.

What is Repare Therapeutics Inc’s market cap?

Repare Therapeutics Inc’s market cap is $76.47M.

When is Repare Therapeutics Inc’s upcoming earnings report date?

Repare Therapeutics Inc’s upcoming earnings report date is Mar 03, 2026 which is in 109 days.

How were Repare Therapeutics Inc’s earnings last quarter?

Currently, no data Available

Is Repare Therapeutics Inc overvalued?

According to Wall Street analysts Repare Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Repare Therapeutics Inc pay dividends?

Repare Therapeutics Inc does not currently pay dividends.

What is Repare Therapeutics Inc’s EPS estimate?

Repare Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Repare Therapeutics Inc have?

Repare Therapeutics Inc has 42,959,170 shares outstanding.

What happened to Repare Therapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Repare Therapeutics Inc?

Currently, no hedge funds are holding shares in RPTX

Repare Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-69.96%

Trailing 12-Months

Asset Growth

-44.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Repare Therapeutics Inc

Repare Therapeutics is a clinical-stage biotechnology company focused on developing precision medicine for patients with cancer. The company specializes in the discovery and development of therapeutics that target DNA damage response mechanisms, leveraging its proprietary platform to identify and advance novel drug candidates. Repare Therapeutics is primarily involved in the oncology sector, aiming to improve treatment outcomes for patients with genetically defined cancers through its innovative product pipeline.

Repare Therapeutics (RPTX) Earnings & Revenues

Historic Earnings Reports

RPTX Stock 12 Month Forecast

Average Price Target

$3.00

▲(74.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,1.9292307692307693,2.0184615384615388,2.1076923076923078,2.1969230769230768,2.286153846153846,2.3753846153846156,2.4646153846153847,2.5538461538461537,2.643076923076923,2.7323076923076925,2.8215384615384616,2.9107692307692306,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,1.9292307692307693,2.0184615384615388,2.1076923076923078,2.1969230769230768,2.286153846153846,2.3753846153846156,2.4646153846153847,2.5538461538461537,2.643076923076923,2.7323076923076925,2.8215384615384616,2.9107692307692306,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,1.9292307692307693,2.0184615384615388,2.1076923076923078,2.1969230769230768,2.286153846153846,2.3753846153846156,2.4646153846153847,2.5538461538461537,2.643076923076923,2.7323076923076925,2.8215384615384616,2.9107692307692306,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >